Suzanne F. Jones

IL-6 and Its Soluble Receptor Orchestrate a Temporal Switch in the Pattern of Leukocyte Recruitment Seen during Acute Inflammation

Suzanne M. Hurst, Thomas S. Wilkinson, Rachel M. McLoughlin et al. · Immunity · 2001 · 813 citations · Full text

Life Sciences, Cell Biology, Immunology +17

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Jeffrey J. Wallin, Johanna C. Bendell, Roel Funke et al. · Nature Communications · 2016 · 713 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

Howard A. Burris, Herbert I. Hurwitz, Elizabeth Claire Dees et al. · Journal of Clinical Oncology · 2005 · 625 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

Ian E. Krop, Muralidhar Beeram, Shanu Modi et al. · Journal of Clinical Oncology · 2010 · 596 citations

Medicine, Oncology, Pharmacology +17

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

Josep Tabernero, Federico Rojo, Emiliano Calvo et al. · Journal of Clinical Oncology · 2008 · 532 citations

Medicine, Oncology, Pharmacology +17